170 related articles for article (PubMed ID: 37509319)
1. Cyclin-Dependent Kinase 4/6 Inhibitors and Dermatologic Adverse Events: Results from the EADV Task Force "Dermatology for Cancer Patients" International Study.
Sollena P; Vasiliki N; Kotteas E; Stratigos AJ; Fattore D; Orlandi A; Mannino M; Di Pumpo M; Fida M; Starace M; Apalla Z; Romano MC; Riganti J; Segura S; Martinez AF; Fabbrocini G; Sibaud V; Peris K; On Behalf Of The Eadv Task Force Dermatology For Cancer Patients
Cancers (Basel); 2023 Jul; 15(14):. PubMed ID: 37509319
[TBL] [Abstract][Full Text] [Related]
2. Vitiligo-like lesions in patients with advanced breast cancer treated with cycline-dependent kinases 4 and 6 inhibitors.
Sollena P; Nikolaou V; Soupos N; Kotteas E; Voudouri D; Stratigos AJ; Fattore D; Annunziata MC; Orlandi A; Di Nardo L; Apalla Z; Deilhes F; Romano MC; Fabbrocini G; Sibaud V; Peris K;
Breast Cancer Res Treat; 2021 Jan; 185(1):247-253. PubMed ID: 32914354
[TBL] [Abstract][Full Text] [Related]
3. Dermatologic toxicities to inhibitors of cyclin-dependent kinases CDK 4 and 6: An updated review for clinical practice.
Sibaud V; Sollena P
Ann Dermatol Venereol; 2023 Sep; 150(3):208-212. PubMed ID: 37586898
[TBL] [Abstract][Full Text] [Related]
4. Safety of CDK4/6 inhibitors and concomitant radiation therapy in patients affected by metastatic breast cancer.
Visani L; Livi L; Ratosa I; Orazem M; Ribnikar D; Saieva C; Becherini C; Salvestrini V; Scoccimarro E; Valzano M; Cerbai C; Desideri I; Bernini M; Orzalesi L; Nori J; Bianchi S; Morandi A; Meattini I
Radiother Oncol; 2022 Dec; 177():40-45. PubMed ID: 36349599
[TBL] [Abstract][Full Text] [Related]
5. Clinical outcomes of tucidinostat-based therapy after prior CDK4/6 inhibitor progression in hormone receptor-positive heavily pretreated metastatic breast cancer.
Zhou J; Wu X; Zhang H; Wang X; Yuan Y; Zhang S; Jiang Z; Wang T
Breast; 2022 Dec; 66():255-261. PubMed ID: 36375386
[TBL] [Abstract][Full Text] [Related]
6. Clinical associations and classification of immune checkpoint inhibitor-induced cutaneous toxicities: a multicentre study from the European Academy of Dermatology and Venereology Task Force of Dermatology for Cancer Patients.
Nikolaou VA; Apalla Z; Carrera C; Fattore D; Sollena P; Riganti J; Segura S; Freites-Martinez A; Lallas K; Romano MC; Oikonomou C; Starace M; Dimopoulos MA; Kyrgidis A; Lazaridou E; Giavedoni P; Annunziata MC; Peris K; Echeverría M; Lopez-Tujillo E; Syrigos K; Papageorgiou C; Podlipnik S; Fabbrocini G; Torre AC; Kemanetzi C; Villa-Crespo L; Lallas A; Stratigos AJ; Sibaud V
Br J Dermatol; 2022 Dec; 187(6):962-969. PubMed ID: 35861701
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the Effectiveness and Clinical Outcome of Everolimus Followed by CDK4/6 Inhibitors with the Opposite Treatment Sequence in Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer.
Jeong H; Jeong JH; Kim JE; Ahn JH; Jung KH; Kim SB
Cancer Res Treat; 2022 Apr; 54(2):469-477. PubMed ID: 34176251
[TBL] [Abstract][Full Text] [Related]
8. Multi-center retrospective review of vitiligo-like lesions in breast cancer patients treated with cyclin-dependent kinase 4 and 6 inhibitors.
Bang AS; Fay CJ; LeBoeuf NR; Etaee F; Leventhal JS; Sibaud V; Arbesman J; Wang JY; Kwong BY
Breast Cancer Res Treat; 2024 Apr; 204(3):643-647. PubMed ID: 38224427
[TBL] [Abstract][Full Text] [Related]
9. Practical Treatment Strategies and Future Directions After Progression While Receiving CDK4/6 Inhibition and Endocrine Therapy in Advanced HR
Sammons S; Shastry M; Dent S; Anders C; Hamilton E
Clin Breast Cancer; 2020 Feb; 20(1):1-11. PubMed ID: 31780379
[TBL] [Abstract][Full Text] [Related]
10. Cutaneous toxicities occurring during palbociclib (CDK4/6 inhibitor) and endocrine therapy in patients with advanced breast cancer: a single-centre experience.
Chawla S; Hill A; Fearfield L; Johnston S; Parton M; Heelan K
Breast Cancer Res Treat; 2021 Jul; 188(2):535-545. PubMed ID: 33683521
[TBL] [Abstract][Full Text] [Related]
11. Real-world outcomes from use of CDK4/6 inhibitors in the management of advanced/metastatic breast cancer in Asia.
Low JL; Lim E; Bharwani L; Wong A; Wong K; Ow S; Lim SE; Lee M; Choo J; Lim J; Chan G; Walsh RJ; Muthu V; Ngoi N; Chong W; Tan SH; Lee SC
Ther Adv Med Oncol; 2022; 14():17588359221139678. PubMed ID: 36570409
[TBL] [Abstract][Full Text] [Related]
12. Cyclin-dependent kinase 4/6 inhibitor treatment use in women treated for advanced breast cancer: Integrating ASCO/NCODA patient-centered standards in a community pharmacy.
Marineau A; St-Pierre C; Lessard-Hurtubise R; David MÈ; Adam JP; Chabot I
J Oncol Pharm Pract; 2023 Jul; 29(5):1144-1153. PubMed ID: 35642282
[TBL] [Abstract][Full Text] [Related]
13. Phase I/II Trial of Exemestane, Ribociclib, and Everolimus in Women with HR
Bardia A; Hurvitz SA; DeMichele A; Clark AS; Zelnak A; Yardley DA; Karuturi M; Sanft T; Blau S; Hart L; Ma C; Rugo HS; Purkayastha D; Moulder S
Clin Cancer Res; 2021 Aug; 27(15):4177-4185. PubMed ID: 33722897
[TBL] [Abstract][Full Text] [Related]
14. Incidence of and risk factors for non-hematologic toxicity with combined radiotherapy and CDK4/6 inhibitors in metastatic breast cancer using dose-volume parameters analysis: a multicenter cohort study.
Kawamoto T; Shikama N; Imano N; Kubota H; Kosugi T; Sekii S; Harada H; Yamada K; Naoi Y; Miyazawa K; Hirano Y; Wada Y; Tonari A; Saito T; Uchida N; Araki N; Nakamura N
Breast Cancer; 2023 Mar; 30(2):282-292. PubMed ID: 36528759
[TBL] [Abstract][Full Text] [Related]
15. Pharmacoeconomic evaluations of CDK4/6 inhibitors plus endocrine therapy for advanced hormone receptor-positive (HR+) and human epidermal growth factor receptor-2 negative (HER2-) breast cancer: a systematic review.
Zhu L; Wang M; Luo X; Li H; Shan H; Du Q; Zhai Q
Ann Transl Med; 2022 Feb; 10(4):233. PubMed ID: 35280368
[TBL] [Abstract][Full Text] [Related]
16. Place in Therapy of Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: A Targeted Literature Review.
Zhao M; Hanson KA; Zhang Y; Zhou A; Cha-Silva AS
Target Oncol; 2023 May; 18(3):327-358. PubMed ID: 37074594
[TBL] [Abstract][Full Text] [Related]
17. Emerging Skin Toxicities in Patients with Breast Cancer Treated with New Cyclin-Dependent Kinase 4/6 Inhibitors: A Systematic Review.
Silvestri M; Cristaudo A; Morrone A; Messina C; Bennardo L; Nisticò SP; Mariano M; Cameli N
Drug Saf; 2021 Jul; 44(7):725-732. PubMed ID: 33959899
[TBL] [Abstract][Full Text] [Related]
18. Real-world Outcomes of Cyclin-dependent Kinase Inhibitors Continued Beyond First Disease Progression in Hormone Receptor-positive Metastatic Breast Cancer.
Samuel Eziokwu A; Varella L; Lynn Kruse M; Jia X; Moore HCF; Thomas Budd G; Abraham J; Montero AJ
Clin Breast Cancer; 2021 Jun; 21(3):205-209. PubMed ID: 33189562
[TBL] [Abstract][Full Text] [Related]
19. Real world incidence and management of adverse events in patients with HR+, HER2- metastatic breast cancer receiving CDK4 and 6 inhibitors in a United States community setting.
Price GL; Sudharshan L; Ryan P; Rajkumar J; Sheffield KM; Nash Smyth E; Morato Guimaraes C; Rybowski S; Cuyun Carter G; Gathirua-Mwangi WG; Huang YJ
Curr Med Res Opin; 2022 Aug; 38(8):1319-1331. PubMed ID: 35535675
[TBL] [Abstract][Full Text] [Related]
20. Case report:
Pan B; Hao Z; Xu Y; Wang Z; Yao R; Wang X; Ren C; Zhou Y; Sun Q; Huo L
Front Oncol; 2022; 12():1095779. PubMed ID: 36620595
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
